PaxMedica Logo.png
  • About

  • Focus

    • ASD
    • FXTAS
  • Pipeline

  • HAT

  • News

  • Contact

  • More

    Use tab to navigate through the menu items.

    News

    PaxMedica Plans to Initiate Phase 1B Study for PAX-101 in Patients with Long COVID-19 Syndrome - January 7, 2022

    PaxMedica selected by American Academy of Child and Adolescent Psychiatry (AACAP) to Present Data from its Recent Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD) in the Research Pipeline Program - August 19, 2021

    PaxMedica Announces Positive Results from Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD) - February 9, 2021

    PaxMedica Receives FDA Orphan Drug Designation for Use of PAX-101 (IV suramin) in a Rare Tropical Disease - February 2, 2021

    PaxMedica Logo.png

    About

    Focus

    Pipeline

    News

    Investors

    Contact

     Legal Notices  |  © 2020 by PaxMedica